Patients with acute hypoxaemic respiratory failure who receive oxygen via a helmet interface likely have better survival rates than those given standard oxygen therapy, a…
Molnupiravir may cut the risk of long COVID symptoms as well as post-acute death, regardless of a patient’s vaccination status or prior infection, US epidemiologists…
Leading doctors have clashed over eligibility criteria for COVID-19 antivirals — specifically nirmatrelvir–ritonavir — following claims many patients were being “short-changed” and left unprotected. Federal…
Nirmatrelvir–ritonavir halves the risk of death and hospitalisation in patients with mild COVID-19 at risk of severe disease — even during the Omicron variant era…
A new oral antiviral might be more favourable than nirmatrelvir–ritonavir in shortening recovery times for at-risk adults with COVID-19, a study suggests. The China-based phase…
Molnupiravir speeds up recovery in high-risk patients with COVID-19 but has no effect on death or hospitalisations compared with usual care, confirm the long-awaited results…
Here is the story of a doctor's life in a city under the control of a paranoid government obsessed with engineering perceptions.
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
